Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

In 2024, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound generated $8 billion and $4.9 billion, respectively. So, this is approximately a $15 billion market ... loss is its impact on meaningful ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...

Recent data shows Eli Lilly's stock price has surged due to strong demand for its weight-loss drug Zepbound, with first-quarter 2024 ... In terms of cross-market impact, institutional investors often ...

On Tuesday, Bernstein analysts maintained a positive outlook on Eli Lilly (NYSE: LLY) shares, reiterating their Outperform rating and a price target of $1,100.00.The pharmaceutical giant ...